WINTON GROUP Ltd Raises Stock Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• WINTON GROUP Ltd increased its Halozyme Therapeutics position by 704.6% in the second quarter, bringing its holdings to 60,348 shares valued at approximately $4.7 million. Institutional investors collectively own 97.79% of the company.
• Halozyme reported strong quarterly results, with EPS of $2.28 versus the $1.79 consensus estimate and revenue of $481 million, up 47.7% year over year. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analyst sentiment remains positive, with nine Buy ratings, three Holds, and one Sell, producing a “Moderate Buy” consensus. However, insiders sold 32,478 shares worth about $3.1 million over the past three months.

WINTON GROUP Ltd lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 704.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 60,348 shares of the biopharmaceutical company's stock after purchasing an additional 52,848 shares during the quarter. WINTON GROUP Ltd owned about 0.05% of Halozyme Therapeutics worth $4,723,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Empowered Funds LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $755,000. Acadian Asset Management LLC purchased a new position in Halozyme Therapeutics in the 1st quarter valued at approximately $195,000. Hsbc Holdings PLC grew its stake in shares of Halozyme Therapeutics by 117.1% in the second quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock worth $522,000 after acquiring an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 174 shares during the period. Finally, Baird Financial Group Inc. increased its position in shares of Halozyme Therapeutics by 6.2% during the second quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock worth $577,000 after acquiring an additional 650 shares during the period. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director owned 40,418 shares of the company's stock, valued at $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 32,478 shares of company stock valued at $3,076,604 over the last three months. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.4%

Shares of NASDAQ HALO opened at $107.00 on Friday. The business has a 50-day moving average of $93.18 and a two-hundred day moving average of $76.75. The company has a market capitalization of $12.14 billion, a price-to-earnings ratio of 31.94, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $111.15. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the business posted $1.54 EPS. The business's revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HALO shares. TD Cowen increased their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, September 2nd. UBS Group reiterated a "buy" rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company's primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.